{"title":"观察性研究中重叠加权倾向得分的混杂校正:简明入门。","authors":"John G Rizk","doi":"10.1080/17512433.2025.2546151","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Overlap weighting has emerged as a valuable method for addressing confounding in observational studies, particularly in real-world data settings characterized by imbalanced covariates and limited overlap between treatment groups. Its ability to produce stable, interpretable estimates makes it an attractive alternative to inverse probability of treatment weighting (IPTW), which can suffer from extreme weights and instability.</p><p><strong>Areas covered: </strong>This report outlines the methodological basis of overlap weighting and contrasts it with IPTW. The limitations of IPTW are illustrated through a clinical example comparing clopidogrel and prasugrel, where substantial baseline differences lead to poor propensity score (PS) overlap. Overlap weighting is discussed as a solution that emphasizes individuals in clinical equipoise (i.e. PS near 0.5), minimizes the influence of outliers, and achieves exact covariate balance.</p><p><strong>Expert opinion: </strong>Overlap weighting is well-suited for observational studies with moderate to poor overlap and can be considered a preferred approach in many real-world contexts. Presenting results from multiple PS methods, including standardized mortality ratio (SMR) weighting, IPTW, PS adjustment, and overlap weighting, can help assess robustness and enhance the credibility of causal inferences.</p>","PeriodicalId":12207,"journal":{"name":"Expert Review of Clinical Pharmacology","volume":" ","pages":"535-541"},"PeriodicalIF":3.0000,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Confounding adjustment with propensity scores for overlap weighting in observational studies: a concise primer.\",\"authors\":\"John G Rizk\",\"doi\":\"10.1080/17512433.2025.2546151\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Introduction: </strong>Overlap weighting has emerged as a valuable method for addressing confounding in observational studies, particularly in real-world data settings characterized by imbalanced covariates and limited overlap between treatment groups. Its ability to produce stable, interpretable estimates makes it an attractive alternative to inverse probability of treatment weighting (IPTW), which can suffer from extreme weights and instability.</p><p><strong>Areas covered: </strong>This report outlines the methodological basis of overlap weighting and contrasts it with IPTW. The limitations of IPTW are illustrated through a clinical example comparing clopidogrel and prasugrel, where substantial baseline differences lead to poor propensity score (PS) overlap. Overlap weighting is discussed as a solution that emphasizes individuals in clinical equipoise (i.e. PS near 0.5), minimizes the influence of outliers, and achieves exact covariate balance.</p><p><strong>Expert opinion: </strong>Overlap weighting is well-suited for observational studies with moderate to poor overlap and can be considered a preferred approach in many real-world contexts. Presenting results from multiple PS methods, including standardized mortality ratio (SMR) weighting, IPTW, PS adjustment, and overlap weighting, can help assess robustness and enhance the credibility of causal inferences.</p>\",\"PeriodicalId\":12207,\"journal\":{\"name\":\"Expert Review of Clinical Pharmacology\",\"volume\":\" \",\"pages\":\"535-541\"},\"PeriodicalIF\":3.0000,\"publicationDate\":\"2025-08-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Expert Review of Clinical Pharmacology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1080/17512433.2025.2546151\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/8/14 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q2\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Review of Clinical Pharmacology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/17512433.2025.2546151","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/8/14 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
Confounding adjustment with propensity scores for overlap weighting in observational studies: a concise primer.
Introduction: Overlap weighting has emerged as a valuable method for addressing confounding in observational studies, particularly in real-world data settings characterized by imbalanced covariates and limited overlap between treatment groups. Its ability to produce stable, interpretable estimates makes it an attractive alternative to inverse probability of treatment weighting (IPTW), which can suffer from extreme weights and instability.
Areas covered: This report outlines the methodological basis of overlap weighting and contrasts it with IPTW. The limitations of IPTW are illustrated through a clinical example comparing clopidogrel and prasugrel, where substantial baseline differences lead to poor propensity score (PS) overlap. Overlap weighting is discussed as a solution that emphasizes individuals in clinical equipoise (i.e. PS near 0.5), minimizes the influence of outliers, and achieves exact covariate balance.
Expert opinion: Overlap weighting is well-suited for observational studies with moderate to poor overlap and can be considered a preferred approach in many real-world contexts. Presenting results from multiple PS methods, including standardized mortality ratio (SMR) weighting, IPTW, PS adjustment, and overlap weighting, can help assess robustness and enhance the credibility of causal inferences.
期刊介绍:
Advances in drug development technologies are yielding innovative new therapies, from potentially lifesaving medicines to lifestyle products. In recent years, however, the cost of developing new drugs has soared, and concerns over drug resistance and pharmacoeconomics have come to the fore. Adverse reactions experienced at the clinical trial level serve as a constant reminder of the importance of rigorous safety and toxicity testing. Furthermore the advent of pharmacogenomics and ‘individualized’ approaches to therapy will demand a fresh approach to drug evaluation and healthcare delivery.
Clinical Pharmacology provides an essential role in integrating the expertise of all of the specialists and players who are active in meeting such challenges in modern biomedical practice.